ETHIZIA
Commercial- Indications
- Surgical bleeding, Internal organ bleeding
Company intelligence / Profile preview
The company’s lead product, the GATT-Patch—a fast hemostatic sealing patch—is moving into clinical trials in Europe and the US. Other pipeline products such as GATT-Powder (for laparoscopic hemostasis) and GATT-Tape (for preventing intestinal anastomotic leakage) are under further development. All leverage a synthetic activated polyoxazoline technology that aims to outperform current fibrin or PEG-polymer based solutions on speed, efficacy, and cost.
4 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GATT Technologies.